Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 28

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 28
---
AvivUniversity and an MD degree from the Hebrew University of Jerusalem, Israel. Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program):Dr. Eric Konofal has served as NLS’s Chief Scientific Officer since February 2021 and as its Interim Chief Medical Officer since January 2024. Dr. Konofal is an IP expert and co -founderof NLS Pharmaceutics Ltd. Dr. Konofal has been active for more than 30 years in the field of sleep research, including narcolepsy and hypersomnia, as a clinician, scientific researcher, and drug hunter. From 2006 to date, Dr. Konofal has served as a Senior Medical Consultant for the Pediatric Sleep Disorders Center and the Child and Adolescent Psychiatry Department at Robert Debré Hospital (APHP). Dr. Konofal received his MD and PhD from University Pierre -MarieCurie in Paris, France. Proposal:The Board of Directors proposes that the following persons shall be elected, on an advisory basis, as members of the senior management: Mr.Ronen Twito (Executive Chairman and Chief Executive Officer) Prof. Michel Revel, MD, PhD (Chief Scientific Officer) Mr.Kfir Molakandov, PhD (Vice President Research and Development) Mr.Ariel Revel, MD (Director of Medical Affairs) Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program) 12.Compensation for the Members of the Board of Directors and Executive Management 12.1 Approval of the Compensation for the Board of Directors Explanation:In connection with the Merger and the renewal of the Board of Directors, the Company is proposing that the previously approved compensation for the Board of Directors is adjusted. The Board of Directors believes that the newly proposed compensation for the Board of Directors adequately reflects their responsibility, expected work load and respective efforts on behalf of the Company. Proposal:The Board of Directors proposes: (i) to approve a new maximum aggregate amount of CHF 200,000 (cash base compensation including all applicable social security contributions) for the fixed compensation of the Board of Directors; (ii) to approve the grant of equity or equity -linkedinstruments with maximum aggregate amount of CHF 350,000(equity or equity linked instruments including all applicable social security contributions) for the compensation of members of the Board of Directors; and (iii) to approve the participation in the purchase of a run -offinsurance policy for the members of the Board of Directors